Ionsys is a drug owned by The Medicines Co. It is protected by 21 US drug patents filed from 2013 to 2017. Out of these, 7 drug patents are active and 14 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2033. Details of Ionsys's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9095706 | Self-test for analgesic product |
Feb, 2033
(7 years from now) | Active |
| US8428709 | Current control for electrotransport drug delivery |
Jun, 2032
(7 years from now) | Active |
| US8428708 | Self-test for analgesic product |
May, 2032
(7 years from now) | Active |
| US8781571 | Switch validation circuit and method |
Mar, 2032
(6 years from now) | Active |
| US9731121 | Switch validation circuit and method |
Oct, 2031
(6 years from now) | Active |
| US9364656 | Method of storing an electrotransport drug delivery device |
Sep, 2031
(6 years from now) | Active |
| US8301238 | Two-part electrotransport device |
Sep, 2031
(6 years from now) | Active |
| US6975902 | Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof |
Apr, 2024
(1 year, 1 month ago) |
Expired
|
| US6881208 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
Apr, 2022
(3 years ago) |
Expired
|
| US6181963 | Transdermal electrotransport delivery device including a cathodic reservoir containing a compatible antimicrobial agent |
Nov, 2019
(5 years ago) |
Expired
|
| US6195582 | Electrotransport device electrode assembly having lower initial resistance |
Jan, 2019
(6 years ago) |
Expired
|
| US6169920 | Iontophoretic drug delivery apparatus |
Jan, 2018
(7 years ago) |
Expired
|
| US5843014 | Display for an electrotransport delivery device |
Dec, 2015
(9 years ago) |
Expired
|
| US7302293 | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
Jun, 2015
(9 years ago) |
Expired
|
| US6171294 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
Jun, 2015
(9 years ago) |
Expired
|
| US7018370 | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
Jun, 2015
(9 years ago) |
Expired
|
| US6216033 | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
Jun, 2015
(9 years ago) |
Expired
|
| US6425892 | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
Jun, 2015
(9 years ago) |
Expired
|
| US6842640 | Electrotransport delivery device with voltage boosting circuit |
Jun, 2015
(9 years ago) |
Expired
|
| US5697896 | Electrotransport delivery device |
Dec, 2014
(10 years ago) |
Expired
|
| US7027859 | Electrotransport delivery device having improved safety and reduced abuse potential |
Sep, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ionsys's patents.
Latest Legal Activities on Ionsys's Patents
Given below is the list of recent legal activities going on the following patents of Ionsys.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 11 Sep, 2023 | US9095706 |
| Maintenance Fee Reminder Mailed Critical | 27 Mar, 2023 | US9095706 |
| Expire Patent Critical | 22 Aug, 2022 | US8781571 |
| Maintenance Fee Reminder Mailed Critical | 07 Mar, 2022 | US8781571 |
| Expire Patent Critical | 20 Sep, 2021 | US9731121 |
| Expire Patent Critical | 31 May, 2021 | US8428709 |
| Expire Patent Critical | 31 May, 2021 | US8428708 |
| Maintenance Fee Reminder Mailed Critical | 05 Apr, 2021 | US9731121 |
| Maintenance Fee Reminder Mailed Critical | 14 Dec, 2020 | US8428708 |
| Maintenance Fee Reminder Mailed Critical | 14 Dec, 2020 | US8428709 |
US patents provide insights into the exclusivity only within the United States, but Ionsys is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ionsys's family patents as well as insights into ongoing legal events on those patents.
Ionsys's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ionsys's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 03, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ionsys Generics:
There are no approved generic versions for Ionsys as of now.
About Ionsys
Ionsys is a drug owned by The Medicines Co. It is used for transdermal delivery of fentanyl hydrochloride. Ionsys uses Fentanyl Hydrochloride as an active ingredient. Ionsys was launched by The Medicines Co in 2006.
Approval Date:
Ionsys was approved by FDA for market use on 22 May, 2006.
Active Ingredient:
Ionsys uses Fentanyl Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fentanyl Hydrochloride ingredient
Treatment:
Ionsys is used for transdermal delivery of fentanyl hydrochloride.
Dosage:
Ionsys is available in system form for iontophoresis, transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MCG BASE/ACTIVATION | SYSTEM | Discontinued | IONTOPHORESIS, TRANSDERMAL |